TGTX

TG TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The bull case is that BRIUMVI remains on a strong adoption curve, the May 6 earnings cycle suggests the commercial engine is still growing, and the June 3 subcutaneous ublituximab data add an incremental product-convenience catalyst that could extend the franchise if it matures into a filing and approval path.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -0.3.

What can break

No detailed broker target-revision tape was present in the packet, so post-print conviction should stay moderate.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $44.50 · Bull $53.00 · Bear $31.50

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-06-07 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $58.38

Why

Momentum93 · Δ7d -0.3

Value51 · Δ7d -0.1

Sentiment26 · Δ7d +1.1

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

-0.3

Δ21d

+0.3

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

-0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+1.1

Δ21d

+0.1

Why this grade

Composite grade C. Momentum 92.5 / Value 51.4 / Sentiment 26.3

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$8.4B

Beta

1.85

Shares Out

153.08M

P/E (TTM)

10.8

P/S (TTM)

8.92

P/FCF (TTM) · Derived

-623.52

Rev YoY

+69.6%

EPS YoY

+297.4%

Gross Margin

+83.1%

Op Margin

+19.3%

Net Debt

$111.74M

Current Ratio

5.81

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology